Lupin Limited (NSE:LUPIN) filed a revised investor presentation on 7 August 2026 under Regulation 30 of the SEBI LODR Regulations, covering unaudited financial results for the quarter ended 30 June 2026 (Q1 FY27), showing consolidated sales of INR 82,172 million, up 33% year-on-year.
Key Highlights
- Consolidated sales for Q1 FY27 reached INR 82,172 million, reflecting 33% year-on-year growth versus INR 61,638 million in Q1 FY26.
- EBITDA stood at INR 24,635 million, with an EBITDA margin of 30.0%, compared to 26.6% in Q1 FY26, as disclosed in the presentation.
- Net income (after adjusting non-controlling interest stake from PAT) was INR 14,150 million, up 16% year-on-year.
- North America sales grew 43% year-on-year to INR 35,908 million, while EMEA rose 65% year-on-year to INR 10,344 million.
About the Company
Lupin Limited (NSE:LUPIN) is a Mumbai-headquartered pharmaceutical company engaged in the development, manufacture, and marketing of branded and generic formulations, active pharmaceutical ingredients, and biosimilars across more than 100 countries. The company operates manufacturing facilities in India, the United States, and Europe, and is listed on both NSE and BSE (Scrip Code: 500257).
Announcement in Detail
The revised investor presentation, filed by Company Secretary Amit Kumar Gupta on 7 August 2026, discloses Q1 FY27 consolidated sales of INR 82,172 million. North America contributed INR 35,908 million (42% of the sales mix, including IP income), while India contributed INR 23,796 million (29%), growing 13.9% year-on-year. R&D spend for the quarter was INR 6,077 million, equivalent to 7.4% of net sales.
On the compliance front, the Ankleshwar facility received a CDSCO approval and an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status. Nagpur Unit I and II received approval from Germany's HLfGP. Remediation at Pithampur Unit II (OAI status) is in progress. Key product developments include EMA approval for NaMuscla in children aged 6-17 years and China approval for Oseltamivir Phosphate oral suspension in partnership with Yabao Pharmaceuticals.
Impact on Investors
The filing shows EBITDA margin expanded to 30.0% in Q1 FY27 from 26.6% in Q1 FY26, which shareholders will observe represents a material improvement in operating profitability. Net income of INR 14,150 million compares with INR 12,191 million in Q1 FY26, a 16% year-on-year increase.
Investors will note that Pithampur Unit II retains OAI status and remediation is ongoing, which represents a regulatory risk factor for that facility. The disclosed capex for Q1 FY27 was INR 2,786 million (3.4% of net sales), and net debt-to-equity was reported at negative 0.12, indicating a net cash position as per the presentation.
Sector / Market Context
India's pharmaceutical exports exceeded USD 27 billion in FY26 according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), with the United States remaining the largest destination market. Generic drug competition and regulatory compliance costs continue to shape profitability across the sector, making EBITDA margin trends a closely watched indicator for large-cap pharma companies listed on NSE and BSE.